HK1148273A1 - Anti-infective pyrimidines and uses thereof - Google Patents

Anti-infective pyrimidines and uses thereof

Info

Publication number
HK1148273A1
HK1148273A1 HK11102295.5A HK11102295A HK1148273A1 HK 1148273 A1 HK1148273 A1 HK 1148273A1 HK 11102295 A HK11102295 A HK 11102295A HK 1148273 A1 HK1148273 A1 HK 1148273A1
Authority
HK
Hong Kong
Prior art keywords
crystalline forms
dihydropyrimidin
methanesulfonamide
naphthalen
dioxo
Prior art date
Application number
HK11102295.5A
Other languages
English (en)
Chinese (zh)
Inventor
‧弗倫特奇
‧赫琴森
‧貝特本納
‧德戈伊
‧唐納
‧卡蒂
‧克魯格
‧劉
‧朗格尼克
‧馬林
‧莫特
‧普拉特
‧蘭多爾夫
‧羅克威
‧斯特沃特
‧瓦格納
‧巴恩斯
‧陳
‧弗蘭齊克二世
‧高
‧海格特
‧亨格維爾德
‧科特基
‧樓
‧張
Original Assignee
艾伯維巴哈馬有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾伯維巴哈馬有限公司 filed Critical 艾伯維巴哈馬有限公司
Publication of HK1148273A1 publication Critical patent/HK1148273A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK11102295.5A 2007-09-17 2011-03-08 Anti-infective pyrimidines and uses thereof HK1148273A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288107P 2007-09-17 2007-09-17
US9679208P 2008-09-13 2008-09-13
PCT/US2008/076592 WO2009039134A1 (en) 2007-09-17 2008-09-17 Anti-infective pyrimidines and uses thereof

Publications (1)

Publication Number Publication Date
HK1148273A1 true HK1148273A1 (en) 2011-09-02

Family

ID=40308557

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11102295.5A HK1148273A1 (en) 2007-09-17 2011-03-08 Anti-infective pyrimidines and uses thereof
HK11110421.5A HK1156033A1 (en) 2007-09-17 2011-10-03 Anti-infective pyrimidines and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11110421.5A HK1156033A1 (en) 2007-09-17 2011-10-03 Anti-infective pyrimidines and uses thereof

Country Status (22)

Country Link
US (3) US8188104B2 (de)
EP (3) EP2203431B1 (de)
JP (3) JP5734655B2 (de)
CN (4) CN102746240B (de)
AT (1) ATE519746T1 (de)
CA (2) CA2849420C (de)
CY (3) CY1115514T1 (de)
DK (3) DK2368882T3 (de)
ES (3) ES2523864T3 (de)
HK (2) HK1148273A1 (de)
HR (2) HRP20110809T1 (de)
HU (1) HUS1500013I1 (de)
LT (1) LTC2203431I2 (de)
LU (1) LU92666I2 (de)
MX (1) MX2010002902A (de)
NL (1) NL300729I1 (de)
NO (1) NO2015011I1 (de)
PL (3) PL2203431T3 (de)
PT (3) PT2203431E (de)
RU (2) RU2014147354A (de)
SI (2) SI2368882T1 (de)
WO (1) WO2009039134A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2368882T1 (sl) 2007-09-17 2015-02-27 Abbvie Bahamas Ltd. Antiinfekcijski pirimidini in njihove uporabe
RU2543620C2 (ru) 2007-09-17 2015-03-10 Эббви Бахамаз Лтд. Производные урацила или тимина для лечения гепатита с
RU2542099C2 (ru) 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
BRPI0916233A2 (pt) * 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais
CN102164909A (zh) 2008-09-26 2011-08-24 弗·哈夫曼-拉罗切有限公司 用于治疗hcv的吡啶或吡嗪衍生物
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
EP2389362B1 (de) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylaminderivate und deren medizinische verwendung
RU2552533C2 (ru) * 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
MX2011011112A (es) 2009-04-25 2011-11-18 Hoffmann La Roche Compuestos antivirales heterociclicos.
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
TW201103545A (en) 2009-06-24 2011-02-01 Hoffmann La Roche Heterocyclic antiviral compound
EP2480533A1 (de) 2009-09-21 2012-08-01 F. Hoffmann-La Roche AG Heterocyclische verbindungen als viruzide
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
CA2778206A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
MX2012006513A (es) * 2009-12-14 2012-07-17 Hoffmann La Roche Compuestos heterociclicos antivirales.
WO2011072791A1 (de) * 2009-12-14 2011-06-23 Merck Patent Gmbh Inhibitoren der sphingosinkinase
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
EP3133059A1 (de) 2010-04-19 2017-02-22 Oryzon Genomics, S.A. Lysinspezifische demethylase-1-hemmer und deren verwendung
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
UA115025C2 (uk) 2010-07-16 2017-09-11 Еббві Айрленд Анлімітед Компані Спосіб одержання противірусних сполук
AU2011278926B2 (en) 2010-07-16 2014-09-25 Abbvie Ireland Unlimited Company Phosphine ligands for catalytic reactions
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Npy y5受容体拮抗作用を有するヘテロ環誘導体
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (de) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysindemethylase-hemmer für myeloproliferative erkrankungen
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ. アー. Lsd1阻害剤としての(ヘテロ)アリールシクロプロピルアミン化合物
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
BR112014005617A2 (pt) * 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
EP2887941B1 (de) 2012-08-21 2018-07-11 AbbVie Ireland Unlimited Company Verfahren zur herstellung antiviraler verbindungen
EA032913B1 (ru) * 2012-10-18 2019-08-30 Эббви Инк. Препараты производных пиримидиндиона
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
BR112018068688B1 (pt) * 2016-03-17 2023-02-14 Fmc Corporation Processo para converter enantiômero s em sua forma racêmica, composto e uso do mesmo
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017202207A1 (zh) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5162326A (en) * 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
NL9001075A (de) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (de) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Urazil-Derivate und diese als aktiven Bestandteil enthaltende Herbizide
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
DK1237878T3 (da) 1999-12-06 2007-07-30 Hoffmann La Roche 4-pyrimidinyl-N-acyl-L-phenylanin
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
IL167956A (en) * 2000-02-04 2009-02-11 Sumitomo Chemical Co Isocyanate compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ534811A (en) * 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
NZ539823A (en) * 2002-11-28 2008-04-30 Schering Aktiengessellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
TW200505872A (en) * 2003-06-13 2005-02-16 Lg Life Science Ltd Hepatitis C virus inhibitors
BRPI0413234A (pt) * 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP1771169A1 (de) * 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Verfahren zur behandlung von hepatitis c
AR057986A1 (es) * 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
RU2543620C2 (ru) * 2007-09-17 2015-03-10 Эббви Бахамаз Лтд. Производные урацила или тимина для лечения гепатита с
SI2368882T1 (sl) 2007-09-17 2015-02-27 Abbvie Bahamas Ltd. Antiinfekcijski pirimidini in njihove uporabe
RU2542099C2 (ru) 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
BRPI0916233A2 (pt) 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais

Also Published As

Publication number Publication date
PL2639226T3 (pl) 2017-02-28
RU2014147354A (ru) 2015-07-10
CN101842360B (zh) 2014-12-17
NO2015011I1 (no) 2015-05-04
SI2368882T1 (sl) 2015-02-27
WO2009039134A1 (en) 2009-03-26
CA2849420C (en) 2016-07-12
EP2203431B1 (de) 2011-08-10
PL2203431T3 (pl) 2012-01-31
NL300729I2 (de) 2016-01-07
LTC2203431I2 (lt) 2017-01-25
PL2368882T3 (pl) 2015-04-30
CA2699986A1 (en) 2009-03-26
RU2539570C2 (ru) 2015-01-20
DK2368882T3 (en) 2014-12-01
CN102746240A (zh) 2012-10-24
PT2203431E (pt) 2011-10-12
HUS1500013I1 (hu) 2016-11-28
EP2639226A1 (de) 2013-09-18
CN104628655A (zh) 2015-05-20
NO2015011I2 (no) 2015-04-22
MX2010002902A (es) 2010-06-02
US20140294766A1 (en) 2014-10-02
JP2010539187A (ja) 2010-12-16
CN101842360A (zh) 2010-09-22
DK2639226T3 (en) 2016-12-19
CY1115514T1 (el) 2016-04-13
CA2699986C (en) 2014-06-17
CN104628654A (zh) 2015-05-20
CY1115893T1 (el) 2017-01-25
EP2639226B1 (de) 2016-08-31
SI2203431T1 (sl) 2011-12-30
CN102746240B (zh) 2017-10-03
CY2015013I2 (el) 2016-04-13
ATE519746T1 (de) 2011-08-15
US20120244119A1 (en) 2012-09-27
JP2013056886A (ja) 2013-03-28
RU2014147354A3 (de) 2018-07-30
ES2592961T3 (es) 2016-12-02
JP5931683B2 (ja) 2016-06-08
ES2368879T3 (es) 2011-11-23
NL300729I1 (de) 2016-01-07
JP2015187106A (ja) 2015-10-29
US9139536B2 (en) 2015-09-22
US8501238B2 (en) 2013-08-06
CA2849420A1 (en) 2009-03-26
PT2639226T (pt) 2016-12-09
HRP20141102T1 (en) 2015-03-13
US8188104B2 (en) 2012-05-29
EP2368882A1 (de) 2011-09-28
JP5734655B2 (ja) 2015-06-17
PT2368882E (pt) 2014-11-27
HK1156033A1 (en) 2012-06-01
RU2010114827A (ru) 2011-10-27
EP2368882B1 (de) 2014-08-13
US20090186912A1 (en) 2009-07-23
DK2203431T3 (da) 2011-11-21
ES2523864T3 (es) 2014-12-02
HRP20110809T1 (hr) 2011-12-31
LU92666I2 (fr) 2015-11-24
CY2015013I1 (el) 2016-04-13
EP2203431A1 (de) 2010-07-07

Similar Documents

Publication Publication Date Title
HUS1500013I1 (hu) Antiinfektiv hatású pirimidinek és alkalmazásuk
IL193725A0 (en) Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
EP2332951A3 (de) 6-modifizierte bicyclische Nukleinsäureanaloga
JO2686B1 (en) Vehicles
TW200612892A (en) Novel compounds
EP1869056A4 (de) Neue 5-substituierte 7-amino-[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-onderivate
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
MX2009007333A (es) Analogos de nucleosidos antivirales.
WO2007052023A3 (en) Novel compounds
TW200731974A (en) Transdermal system for verenicline
TW200618801A (en) Pyrimidine derivatives
NZ705225A (en) Process for preparing antiviral compounds
TW200738723A (en) 1-(1-(2-Ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and salts thereof
WO2006128802A3 (en) 3-methanesulfonylquinolines as gaba-b enhancers
WO2009006267A3 (en) N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
WO2007069050A3 (en) Processes for the preparation of alfuzosin
WO2009091346A3 (en) Stable pharmaceutical formulation and preparation methods
UA95085C2 (ru) Применение варденафила для лечения урологических расстройств
WO2006019673A3 (en) Jiadifenin analogs and uses thereof
GB0617966D0 (en) Novel 2 amino-pyrimidine derivatives, processes for preparing them, pharmaceutical compositions thereof